Targeted Therapy
Approved for: NSCLC
Biomarker: EGFR Exon20 Insertion
Mobocertinib (EXKIVITY) is the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC
FDA-Approved Lung Cancer Treatments
Mobocertinib
I want to give in honor of...
name or relation
Donation Amount
other amount